17th Aug 2018 07:00
FOR IMMEDIATE RELEASE 17 August 2018
Cello Health plc
("Cello" or the "Group")
Notification of Half Year Results
Cello Health plc (AIM: CLL), the global healthcare-focused advisory group, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.
Enquiries:
Cello Health plc | 020 7812 8460 |
Mark Scott, Chief Executive | |
Mark Bentley, Group Finance Director | |
Cenkos Securities plc | 020 7397 8900 |
Mark Connelly | |
Harry Hargreaves | |
Buchanan | 020 7466 5000 |
Mark Court | |
Jamie Hooper | |
Sophie Wills |
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
Related Shares:
CLL.L